ea0020p338 | Diabetes and Cardiovascular | ECE2009
Maheux Pierre
, Allen Elsie
, Ravichandran Shoba
, List James
, Chen Roland
Saxagliptin (SAXA) is a potent, selective dipeptidyl peptidase-4 (DPP-4) inhibitor, specifically designed for extended inhibition of the DPP-4 enzyme. The efficacy and safety of SAXA 5 mg add-on therapy to a thiazolidinedione (TZD), metformin (MET), or an intermediate dose of glibenclamide (GLY), was investigated in patients with inadequately controlled (HbA1c>7.0%) type 2 diabetes mellitus (T2DM) in three randomised, double-blind trials (CV181-013, CV181-014 an...